Market News / Story
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its…
GlobeNewswire ·
GlobeNewswire reports: Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo’s growing portfolio SOLANA BEACH, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…